Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695779 | 1.00 | L3MBTL1 (0.36) | L3MBTL1LMNAMAPK1HTTNPC1 | |
| SCHEMBL695780 | 1.00 | L3MBTL1 (0.36) | L3MBTL1LMNAMAPK1HTTNPC1 | |
| SCHEMBL6970352 | 0.81 | L3MBTL1 (0.39) | L3MBTL1LMNAMAPK1HTTNPC1 | |
| SCHEMBL696078 | 0.81 | L3MBTL1 (0.39) | L3MBTL1LMNAMAPK1HTTNPC1 | |
| SCHEMBL696077 | 0.81 | L3MBTL1 (0.39) | L3MBTL1LMNAMAPK1HTTNPC1 | |
| SCHEMBL5222856 | 0.79 | L3MBTL1 (0.41) | L3MBTL1LMNAMAPK1HTTNPC1 | |
| SCHEMBL5958145 | 0.79 | LMNA (0.36) | L3MBTL1LMNAMAPK1HTTNPC1 | |
| SCHEMBL5958142 | 0.79 | LMNA (0.36) | L3MBTL1LMNAMAPK1HTTNPC1 | |
| SCHEMBL23635747 | 0.78 | L3MBTL1 (0.57) | L3MBTL1LMNAMAPK1HTTNPC1 | |
| SCHEMBL695964 | 0.77 | LMNA (0.47) | L3MBTL1LMNAMAPK1HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101783-A1 | N-(heterocycle-methyl)alkylamine derivative, process for producing the same, and bactericide | KUREHA CORPORATION (JP) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101783-A1 | N-(heterocycle-methyl)alkylamine derivative, process for producing the same, and bactericide | HBZ, ACMSD, HDHD5 | L3MBTL1 1563/4885LMNA 2729/4885MAPK1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.